Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- RAC
- Ann: Race releases complete cardio-protection data & video
Ann: Race releases complete cardio-protection data & video, page-228
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.41 |
Change
0.095(7.22%) |
Mkt cap ! $234.6M |
Open | High | Low | Value | Volume |
$1.32 | $1.41 | $1.32 | $249.8K | 182.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2826 | $1.40 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.43 | 40000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2826 | 1.400 |
1 | 612 | 1.355 |
1 | 40000 | 1.350 |
1 | 13458 | 1.330 |
1 | 20000 | 1.300 |
Price($) | Vol. | No. |
---|---|---|
1.430 | 40000 | 1 |
1.440 | 20000 | 1 |
1.450 | 1030 | 1 |
1.490 | 6375 | 1 |
1.500 | 16689 | 3 |
Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.37 |
  |
Change
0.095 ( 6.64 %) |
|||
Open | High | Low | Volume | ||
$1.34 | $1.41 | $1.32 | 16145 | ||
Last updated 15.53pm 10/05/2024 ? |
Featured News
RAC (ASX) Chart |